medigraphic.com

2017, Number 5

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2017; 55 (5)

The pulmonary hypertension of the chronic kidney disease

Santos-Martínez LE, Orihuela-Rodríguez O, Rodríguez-Almendros NA, Carmona-Ruíz H, Soto-Márquez P, Paniagua-Sierra JR, Saturno-Chiu G, Magaña-Serrano JA

Language: Spanish
References: 43
Page: 621-631
PDF size: 459.04 Kb.


ABSTRACT

Pulmonary hypertension in chronic kidney disease is included in the group 5 of the pulmonary hypertension classification of the World Health Organization. Its mechanism is multifactorial and little known. Its importance has increased due to its impact on survival according to whether they received a kidney transplant, the greater risk of early renal graft loss and major hospital stays. In this review, we analyze the panorama of chronic renal disease in Mexico and Latin America, the epidemiology, pathophysiological mechanisms, the diagnostic process and the treatment of pulmonary hypertension in chronic kidney disease.


REFERENCES

  1. Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohe C, Nickenig G et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-Study. PloS ONE. 2012:7(4):e35310.

  2. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Pediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119.

  3. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J et al. Right heart adaptation to pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D22-33.

  4. Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int. 2013;84:682-92.

  5. Casas-Aparicio G, Castillo-Martínez L, Orea- Tejeda A, Abasta-Jiménez M, Keirns-Davies C, Rebollar-González V. The effect of successful kidney transplantation on ventricular dysfunction and pulmonary hypertension. Transplant Proc. 2010;42(9):3542-48.

  6. Lentine KL, Villines TC, Axelrod D, Kaviratne S, Weir MR, Costa SP. Evaluation and management of pulmonary hypertension in kidney transplant candidates and recipients: concepts and controversies. Transplantation. 2017;101(1):166-81.

  7. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PloS ONE. 2016;11(7):e0158765.

  8. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. Am J Kidney Dis. 2014;63(5):713-35.

  9. de Lusignan S, Tomson C, Harris K, Van Vlymen J, Gallagher H. UK prevalence of chronic kidney disease for the adult population is 6.75% based on two creatinine readings [Erratum]. Nephron Clini Prac. 2012;120:c107.

  10. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden Study 2015. Lancet. 2016;388:1459-44.

  11. Cusumano AM, González C. Chornic kidney disease in Latin America: time to improve screening and detection. Clin J Am Soc Nephrol. 2008;3(2):594-600.

  12. Martins D, Agodoa L, Norris K. Kidney disease in disadvantaged populations. Int J Nephrol. 2012;2012:469265.

  13. Garcia-Garcia G, Gutiérrez-Padilla AJ, Renoirte- Lopez K, Mendoza-Garcia M, Oseguera-Vizcaíno MC, Perez-Gomez HR et al. Chronic kidney disease in homeless persons in Mexico. Kidney Int Suppl. 2013;3:250-53.

  14. Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol. 2013;33:14-22.

  15. Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis. 2014;7:75-88.

  16. Secretaría de Salud. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. Ciudad de México: Secretaría de Salud; 2016. Disponible en: http://www.epidemiologia.salud.gob.mx/doctos/ encuestas/resultados/ENSANUT.pdf.

  17. Villalpando S, Rojas R, Shamah-Levy T, Ávila MA, Gaona B, De la Cruz V et al. Prevalence and distribution on type 2 Diabetes mellitus in Mexican adult population. A probabilistic survey. Salud Publica Mex. 2010;52 suppl I:S19-S26.

  18. Organización para la Cooperación y el Desarrollo Económicos. Cardiovascular Disease and Diabetes: Policies for better Health and quality of care. Washington, D.C.; Organización para la Cooperación y el Desarrollo Económicos; 2015. Disponible en: https://www.oecd.org/mexico/ Cardiovascular-Disease-and-Diabetes-Policies-for- Better-Health-and-Quality-of-Care-Mexico.pdf

  19. Hernández-Ávila M, Gutiérrez JP, Reynoso-Noverón N. Diabetes mellitus en México. El estado de la epidemia. Salud Publica Mex. 2013;55(supl 2):S129-S136.

  20. Sánchez Díaz María del Rocío, Cortés Ramírez Mario, Muñoz Torres Abril, Alanís Cuevas Darío. Sistema de Vigilancia Epidemiológica Hospitalaria de Diabetes Tipo 2 / Cierre anual 2015 de la Secretaría de Salud, Subsecretaría de Prevención y Promoción de la Salud, Dirección General de Epidemiología. Disponible en: http://www.epidemiologia.salud.gob. mx/doctos/infoepid/bol_diabetes/dm2_2015.pdf

  21. Instituto Nacional de Estadística y Geografía. Principales causas de mortalidad por residencia habitual, grupos de edad y sexo del fallecido. Ciudad de México: Instituto Nacional de Estadística y Geografía; 2015. Disponible en: http://www.inegi. org.mx/est/contenidos/proyectos/registros/vitales/ mortalidad/tabulados/PC.asp?t=14&c=11817

  22. United States Renal Data System. 2016 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Volumen 2. Cap. 13.: International Comparison. Ann Arbor, Michigan: United States Renal Data System; 2016.

  23. Sociedad Latinoamericana de Nefrología e Hipertensión. Burden of disease prevalence and incidence of renal disease (ESRD) in Latin America. Panamá, Panamá: Sociedad Latinoamericana de Nefrología e Hipertensión; 2015. Disponible en: http://www.slanh.net/wp-content/uploads/2015/09/ RLADT-WCN-2012.pdf

  24. Amato D, Alvarez-Aguilar C, Castañeda-Limones R, Rodriguez E, Avila-Diaz M, Arreola F et al. Prevalence of chronic kidney disease in an urban Mexican population. Kidney Int. 2005;68 Suppl (97):S11-S17.

  25. The World Bank. Poverty & Equity Data. Washington D.C.: The World Bank; 2016.

  26. Gutiérrez-Padilla AJ, Mendoza-Garcia M, Plascencia-Perez S, Renoirte-Lopez K, Garcia Garcia G, Lloyd A et al. Screening for CKD and cardiovascular disease risk factors using mobile clinics in Jalisco, Mexico. Am J Kidney Dis. 2010;55:474-84.

  27. Lora CM, Daviglus ML, Kusek JW, Porter Am, Ricardo AC, Go AS et al. Chornic kidney disease in United States hispanics: A growing public Health problem. Ethn Dis. 2009;19(4):466-472.

  28. Lam CSP, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increase in pulmonary artery systolic pressure in the general population. Circulation. 2009;119:2663-70.

  29. Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012;98(24):1805-11.

  30. Bolignano D, Rastelli S, Agarwal R, Fliser D, Ortiz A, Wiecek A et al. Pulmonary hypertension in CKD. Am J Kidney Dis. 2013;61(4):612-22.

  31. Yang QM, Bao XR. Pulmonary hypertension in patients with stage 1-3 chronic kidney disease. Genet Mol Res. 2014;13(3):5695-703.

  32. Navaneethan SD, Roy J, Tao K, Brecklin CS, Chen J, Deo R et al. Prevalence, predictors and outcomes of pulmonary hypertension in CKD. J Am Soc Nephrol. 2016;27:877-86.

  33. Thurley PD, Duerden R, Roe S, Pointon K. Rapidly progressive metastatic pulmonary calcification: evolution of changes on CT. Br J Radiol. 2009;82:e155-e159.

  34. Kim NH, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2012;21(123):27-31.

  35. Sofia M, Stanziola AA. Kidney pulmonary hypertension: another road on the map? Multidiscip Respir Med. 2011;6(3):150-152.

  36. Anand IS. Pathophysiology of anemia in heart failure. Heart Failure Clin. 2010;6:279-88.

  37. Opotowsky AR, Ojeda J, Rogers F, Arkles J, Liu T, Forfia PR. Blood pressure response to the Valsalva maneuver. A simple bedside test to determine the hemodynamic basis of pulmonary hypertension. J Am Coll Cardiol. 2010;56(16):1352-53.

  38. Howard LS, Grapsa J, Dawson D, Bellamy M, Chambers JB, Masani ND et al. Echocardiographic assessment of pulmonary hypertension: standard operating procedure. Eur Respir Rev. 2012;21:239-48.

  39. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher K, Solomon SD et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;11(5):685-713.

  40. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE et al. Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:615-21.

  41. Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S et al. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin J Am Soc Nephrol. 2014;9:855-63.

  42. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005;11(1):12-20.

  43. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44-54.




2020     |     www.medigraphic.com